MGF
Mechano Growth Factor (IGF-1Ec)
MGF (Mechano Growth Factor (IGF-1Ec)) is a gh & growth research compound. Locally-produced IGF-1 splice variant that activates muscle satellite cells after mechanical stress — the non-pegylated, ultra-short-acting form.
MGF quick facts
| Reported research dose | 200mcg-400mcg |
| Route | IM or Subq |
| Frequency | 1x Post-workout · Training days |
| Half-life | Minutes (very labile) |
| Forms | Injectable |
| Evidence level | Animal + anecdotal |
Extremely short-lived — dose immediately post-workout at the target muscle. PEG-MGF is the long-acting version.
How MGF works
Locally-produced IGF-1 splice variant that activates muscle satellite cells after mechanical stress — the non-pegylated, ultra-short-acting form.
Proposed benefits
Researched for lean-mass support, recovery, sleep depth, connective-tissue repair and improved body composition via the GH/IGF-1 axis.
Human clinical evidence
- No human trials. It never left preclinical development, so the ceiling on what anyone can claim is a rodent model — and rodent models of this endpoint have a poor record of transferring.
📊 Correlative data
- No human series. Reported use is local injection alongside training, on the reasoning that MGF is what muscle produces after mechanical damage.
- Beyond that, the record is self-reported. Community dosing logs are real information about tolerability and nothing at all about efficacy: nobody posts the cycle where they felt no different, so what survives is a filtered sample that will always look better than the truth.
🧪 How the mechanism reads
- Mechano-Growth Factor is a splice variant of IGF-1 produced by muscle in response to mechanical loading. It activates satellite cells — the resident stem cells that fuse into damaged fibres — which is a genuinely distinct action from IGF-1's general anabolic signalling.
- The mechanism predicts the practical limit that the anecdotal record ignores: unmodified MGF has a half-life measured in minutes in serum, so systemic dosing is largely wasted and local injection is the only thing the biology supports.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
MGF — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- Everything here follows from one fact: these raise GH and therefore IGF-1. The predicted problems are the known consequences of elevated GH/IGF-1, drawn from acromegaly and clinical GH therapy where it HAS been studied — insulin resistance and rising fasting glucose, fluid retention (puffy hands and face, and the ring that stops fitting), carpal tunnel symptoms from that same fluid pressing on the median nerve, and joint aches.
- The proliferation question is the serious one. IGF-1 is a growth signal, and growth signals do not distinguish between tissue you want to grow and tissue you do not. There is no evidence these compounds cause cancer. There is also a clear mechanistic reason not to run them with an active or recent malignancy, and that reasoning does not require a trial to be sound.
What has actually been reported
- Injection-site reactions, transient flushing, tingling and head-rush on dosing — most commonly with the GHRPs, which also release cortisol and prolactin at higher doses.
- Increased hunger is near-universal with the ghrelin-mimetic ones (GHRP-6, MK-677, Hexarelin). That is the mechanism working, not a side effect — the same receptor drives GH release and appetite.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Draw an IGF-1 baseline BEFORE you start. Once you are on, that number is the drug and you have permanently lost the comparison. This is the single highest-value thing on this list and it costs one blood draw.
- Watch fasting glucose and HbA1c, not the scale. Insulin resistance is the most likely thing to move and the one you cannot feel. Re-test at 8–12 weeks. If fasting glucose is climbing, that is your signal to cut the dose or come off — long before anything shows up symptomatically.
- Dose at night, on an empty stomach. GH release is pulsatile and largest during early sleep; food, and carbohydrate in particular, blunts the pulse through insulin. This is not a ritual — it is the same mechanism working with you rather than against you.
- Don't run a secretagogue through a high-carbohydrate surplus. The predicted problem is insulin resistance; adding a large carb load is pushing the same lever from the other end.
- Cycle rather than run continuously. Most of the predicted problems — fluid retention, carpal tunnel, glucose drift — are dose-and-duration dependent and reverse on cessation. Time off is the cheapest safety intervention available.
- If fluid retention is the issue, it usually resolves on a dose reduction long before it needs anything else. Reach for the dose before you reach for a diuretic.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- IGF-1 drawn on-cycle is not your baseline — it is the drug working, and it will read high. If you want a real baseline, draw before starting or after a proper washout.
- Watch fasting glucose and HbA1c, because insulin resistance is the most likely thing to move and the one you will not feel.
- GHRP-6 and Hexarelin can raise prolactin and cortisol; if you are chasing an unexplained prolactin result, this is a candidate.
What it overlaps with
- Stacking two secretagogues that work by the same route is redundancy, not synergy. A GHRH analogue (CJC-1295, Sermorelin, Tesamorelin) plus a ghrelin mimetic (Ipamorelin, GHRP-2, GHRP-6) is the deliberate pairing — two different levers on the same axis. Two GHRH analogues together is paying twice for one lever.
Don't run this if
- Active or recent malignancy — the IGF-1 reasoning above.
- Diabetes or poor glycaemic control, unless you are monitoring fasting glucose and HbA1c and know what you are looking at.
- Untreated diabetic retinopathy.
The honest unknown
- Nobody has run long-term studies of intermittent secretagogue use in healthy adults. The specific unmeasured thing is what years of repeatedly pushing IGF-1 above your natural set point does — not whether a single cycle is tolerable, which it evidently is.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Where to get MGF
See vetted vendors for MGF →MGF — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What MGF moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- IGF-1 (Insulin-like Growth Factor 1) — ↑ expected to rise
This is the point. IGF-1 rising is the compound doing its job — it is the stable downstream readout of a GH pulse.
What to do: Test it before you start and again at 6–8 weeks. It is the only number that tells you whether the product was real and the dose was enough. - Growth Hormone, Serum — ✕ unreliable here
A random GH level is close to meaningless here. GH is secreted in pulses during deep sleep and sits undetectable between them, so a daytime draw catches a trough almost every time — including when the compound is working perfectly.
What to do: Do not use GH to judge a secretagogue. Read IGF-1 instead. - Fasting Insulin — ↑ expected to rise
GH is a counter-regulatory hormone: it opposes insulin. Fasting insulin and glucose drifting up is the predicted trade-off, not a surprise.
What to do: Check fasting insulin and HbA1c at baseline and again at 8–12 weeks. This is the marker that decides whether you keep running it. - HbA1c (Hemoglobin A1c) — ↑ expected to rise
Same mechanism, longer window — a slow drift rather than a jump.
What to do: Pair it with fasting insulin; either alone can mislead. - Free T4 (Thyroxine) — ↓ expected to fall
GH accelerates the peripheral conversion of T4 to T3, so free T4 can fall while free T3 holds or rises. Read alone it looks like new hypothyroidism, and it usually isn't.
What to do: Run a full thyroid panel rather than TSH alone before concluding anything.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for MGF — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →Everything above follows from one fact: these raise GH and therefore IGF-1. Nothing here needs a trial of the specific molecule.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
Get the complete breakdown for MGF — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →Bloodwork to run alongside MGF
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| IGF-1 (Insulin-like Growth Factor 1) | The trap: MGF is a LOCAL splice variant. Flat systemic IGF-1 doesn't mean it failed |
| Fasting Insulin | Baseline before anything acting on the IGF axis |
| Comprehensive Metabolic Panel (CMP) | Organ function baseline |
The Athletic Performance & Recovery panel covers these in one order — 12 markers, $207.90 with the discount applied.
Check results you already have → · All 102 markers A–Z
MGF — frequently asked questions
What is MGF?
MGF (Mechano Growth Factor (IGF-1Ec)) is a gh & growth research compound. Locally-produced IGF-1 splice variant that activates muscle satellite cells after mechanical stress — the non-pegylated, ultra-short-acting form.
Is the full MGF protocol on this page?
The reported research dose is on this page, along with how MGF works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside the Academy.
What is the half-life of MGF?
MGF has an approximate half-life of Minutes (very labile), which is part of what determines how often it's dosed.
What's the evidence behind MGF?
Current evidence level: Animal + anecdotal. MGF is offered for research purposes only and is not an approved medicine.
Want Coach Cam's exact MGF protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →What MGF is used for
MGF appears under 1 goal in the Vault’s goal router, grouped by the mechanism it works through rather than by how much trial evidence exists. Each link opens that pathway in full, with the alternatives beside it and the bloodwork that tests it.